Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

69825 NovaBlue Competent Cells - Novagen

NovaBlue is a K-12 strain ideally suited as an initial cloning host due to its high transformation efficiency, blue/white screening capability (with appropriate plasmids) and recA endA mutations.

NovaBlue Competent Cells - Novagen : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
69825
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Products

RéférenceConditionnement Qté
69825-3 Flacon en verre 0.4 ml
69825-4 Flacon en verre 1 ml
Description
OverviewNovaBlue is a K-12 strain ideally suited as an initial cloning host due to its high transformation efficiency, blue/white screening capability (with appropriate plasmids) and recA endA mutations, which result in high yields of excellent quality plasmid DNA. The DE3 lysogen of NovaBlue is potentially useful as a stringent host due to the presence of the lacIq repressor encoded by the F episome. Blue/white screening is not possible with NovaBlue(DE3) due to the presence of the lacZ α-peptide coding sequences in the lysogenic phage.
This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
Catalogue Number69825
Brand Family Novagen®
References
Product Information
Components
Guaranteed efficiencyGuaranteed efficiency: > 1 x 10⁸ cfu/μg
Quality LevelMQ100
Applications
Biological Information
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Multiple Toxicity Values, refer to MSDS
Storage ≤ -70°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
69825-3 04055977273984
69825-4 04055977273991

Documentation

NovaBlue Competent Cells - Novagen FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

NovaBlue Competent Cells - Novagen Certificats d'analyse

TitreNuméro de lot
69825

Citations

Titre
  • Graham Christie, Milena Lazarevska and Christopher R. Lowe. (2008) Functional consequences of amino acid substitutions to GerVB, a component of the Bacillus megaterium spore germinant receptor. Journal of Bacteriology 190, 2014-2022.
  • Jennifer L. Farmer, et al. (2008) Galectin 15 (LGALS15) functions in trophectoderm migration and attachment. Federation of American Societies for Experimental Biology Journal 22, 548-560.
  • Brantley R. Herrin, et al. (2008) Structure and specificity of lamprey monoclonal antibodies. Procedings of the National Academy of Science 105, 2040-2045.
  • Samuel A. Shelburne, III, et al. (2008) A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Procedings of the National Academy of Science 105, 1698-1703.
  • Phillip J. Monaghan, David Leys and Nigel S. Scrutton. (2007) Mechanistic aspects and redox properties of hyperthermophilic L-proline dehydrogenase from Pyrococcus furiosus related to dimethylglycine dehydrogenase/oxidase. Federation of American Societies for Experimental Biology Journal 274, 2070-2087.
  • Xiuhua Pang and Susan T. Howard. (2007) Regulation of the α-crystallin gene acr2 by the mprAB two-component system of Mycobacterium tuberculosis. Journal of Bacteriology 189, 6213-6221.
  • Pernilla Larsson Birgander, et al. (2005) Nucleotide-dependent formation of catalytically competent dimers from engineered monomeric ribonucleotide reductase protein R1. Journal of Biological Chemistry 280, 14997-15003.
  • Catherine Paradis-Bleau, Francois Sanschagrin and Roger C. Levesque. (2005) Peptide inhibitors of the essential cell division protein FtsA. Protein Engineering Design and Selection 18, 85-91.
  • Francois Sanschagrin and Roger C. Levesque. (2005) A specific peptide inhibitor of the class B metallo-{beta}-lactamase L-1 from Stenotrophomonas maltophilia identified using phage display. Journal of Antimicrobial Chemotherapy 55, 252-255.
  • Laura I. Katona, et al. (2004) The Fur homologue in Borrelia burgdorferi. Journal of Bacteriology 186, 6443-6456.
  • Sharmila Sivendran, et al. (2004) Two novel mutant human adenylosuccinate lyases (ASLs) associated with autism and characterization of the equivalent mutant Bacillus subtilis ASL. Journal of Biological Chemistry 279, 53789-53797.
  • Deanne M. Compaan and W. Ross Ellington. (2003) Functional consequences of a gene duplication and fusion event in an arginine kinase. 206, 1545-1556.
  • Yusuf Kaya and James Ofengand. (2003) A novel unanticipated type of pseudouridine synthase with homologs in bacteria, archaea, and eukarya. RNA 9, 711-721.
  • Michael B. Murphy, et al. (2003) An improved method for the in vitro evolution of aptamers and applications in protein detection and purification. Nucleic Acids Research 31, e110-.
  • Ahmed El Zoeiby, et al. (2003) Identification of novel inhibitors of Pseudomonas aeruginosa MurC enzyme derived from phage-displayed peptide libraries. Journal of Antimicrobial Chemotherapy 51, 531-543.
  • Paul L. DeAngelis and Amy J. Padgett-McCue. (2000) Identification and molecular cloning of a chondroitin synthase from Pasteurella multocida type F. Journal of Biological Chemistry 275, 24124-24129.
  • In-Hong Choi, et al. (1997) Clonal expansion of CD8+ T cells in Kawasaki disease. Journal of Immunology 159, 481-486.
  • Thomas P. Shanley, et al. (1997) Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. Journal of Immunology 158, 3439-3448.
  • Y. Xu, et al. (1995) High-yield bacterial expressio, purification, and functional reconstitution of the tricarboxylate transport protein from rat liver mitochondria. Biochemical and Biophysical Research Communications 207, 783-789.
    		•

    Protocoles Utilisateur

    Titre
    TB009 Competent Cells